{
  "links": "https://www.ycombinator.com/companies/circumvent",
  "name": "Circumvent",
  "headline": "Utilizing monogenic disorders to inform and solve highly complexâ¦",
  "batch": "S18",
  "description": null,
  "activity_status": "Active",
  "website": "https://www.circumventpharmaceuticals.com/",
  "founded_date": null,
  "team_size": 6.0,
  "location": null,
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:neurotechnology; industry:biotech; industry:genomics",
  "founders": [],
  "status": true,
  "markdown": "raw_markdown=\"top of page\\n![Circumvent_Logo-01.png](https://static.wixstatic.com/media/8cf47c_e286387e91c748aab201e7933ddc0caf~mv2.png/v1/fill/w_200,h_52,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Circumvent_Logo-01.png)\\n  * [Home](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * [About](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * [Patients](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * [Investors](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * [Team](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * More\\n\\n\\nUse tab to navigate through the menu items.\\n  * [ABOUT](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * [APPROACH](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * [PATIENTS](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * [INVESTORS](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * [INVESTORS](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * [PARTNERS](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * [TEAM](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * [TEAM](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n  * [CONTACT](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>)\\n\\n\\n![](https://static.wixstatic.com/media/8cf47c_5b88259224c94e6e8f86a331f645fc43f000.jpg/v1/fill/w_1080,h_600,al_c,q_85,usm_0.33_1.00_0.00,enc_avif,quality_auto/8cf47c_5b88259224c94e6e8f86a331f645fc43f000.jpg)\\nCIRCUMVENT\\n# Developing precision medicines for neurodegenerative disease\\n![Dial.png](https://static.wixstatic.com/media/8cf47c_268dcd55d6ba41779fe5a776056582da~mv2.png/v1/fill/w_132,h_135,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Dial.png)\\nABOUT\\n![shutterstock_726758389 \\\\[Converted\\\\]-01.jp](https://static.wixstatic.com/media/8cf47c_74e6e0d5e1aa4237afb64653322adc8b~mv2.jpg/v1/fill/w_1001,h_475,al_c,q_85,enc_avif,quality_auto/8cf47c_74e6e0d5e1aa4237afb64653322adc8b~mv2.jpg)\\n## ABOUT\\nIn the next 20 years, neurodegenerative disease is expected to overtake cancer as the second leading cause of death worldwide. At the same time, progress in developing disease-modifying treatments has been slowed by the lack of novel insights into driver mechanisms of disease. Circumvent was formed with the mission of developing precision medicines for neurodegenerative disease, starting with Batten Disease.\\nAPPROACH\\n## APPROACH\\nWe built an experienced team of scientists and clinicians to focus on diseases with high-fidelity, predictive animal models, a clear clinical development path, and the potential to reach the market quickly. Through our research and development of treatments for Batten Disease, we’ve uncovered new insights into brain-cell dysfunction that are common to numerous forms of neurological disease. We are now applying these insights across a variety of related diseases with diligence and precision.\\n![shutterstock_1197119914.jpg](https://static.wixstatic.com/media/8cf47c_8482c4e53b0a4b3594e5d0107d522ec4~mv2.jpg/v1/crop/x_60,y_56,w_5000,h_2769/fill/w_1000,h_556,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_1197119914.jpg)\\n## We've developed novel insights into:\\n![pasted image 0.png](https://static.wixstatic.com/media/8cf47c_c01544d4f1de4a1eb8e3caa8932f4d3d~mv2.png/v1/fill/w_105,h_79,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/pasted%20image%200.png)\\nSynaptic function Protein localization Lysosomal function Autophagy\\n![shutterstock_1197120001.jpg](https://static.wixstatic.com/media/8cf47c_f726d65afb7848109b0b23f0c803e764~mv2.jpg/v1/fill/w_132,h_74,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/8cf47c_f726d65afb7848109b0b23f0c803e764~mv2.jpg)\\n![Embryonic Stem Cells](https://static.wixstatic.com/media/5c3f1e5a1ebf435bbc152173d50d7ea9.jpg/v1/fill/w_94,h_75,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/5c3f1e5a1ebf435bbc152173d50d7ea9.jpg)\\n## The Palmitoylome\\nOur search for underlying biology has allowed us to characterize the palmitoylome with precision\\n\\u200b\\nWe are investigating several therapeutic strategies for modulating the palmitoylome\\n\\u200b\\nThis effort has broad potential to yield medicines for both rare and common forms of neurodegenerative disease\\n![Blood Test](https://static.wixstatic.com/media/a5b6e8edfb63432792f48f95895df268.jpg/v1/fill/w_112,h_75,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/a5b6e8edfb63432792f48f95895df268.jpg)\\n## The Synaptome\\nOur investigation into the palmitoylome has given us unique insights into the architecture of the synaptome and its effect on synaptic function\\n\\u200b\\n>50% of palmitoylated proteins are synaptic proteins, and conversely, >40% of synaptic proteins are palmitoylated \\n\\u200b\\nModulating palmitoylation has effects on synaptic plasticity and neuronal differentiation, with broad therapeutics potential\\n## PATIENTS\\nOur priority is to meet the needs of patients through the development of precision medicines for rare neurological diseases. We listen to patients and caregivers and solicit advice to better understand expectations for therapies and guide our research and development efforts. Circumvent’s current drug programs are being developed for Batten Disease and other rare neurological disorders.\\n![shutterstock_386773696.jpg](https://static.wixstatic.com/media/8cf47c_e107cebcb2bb4375a728edf7387082e5~mv2.jpg/v1/crop/x_251,y_430,w_4679,h_2596/fill/w_150,h_83,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/shutterstock_386773696.jpg)\\nPATIENTS\\n## What is Batten Disease?\\nBatten disease is a group of rare neurodegenerative diseases that typically present during childhood and progress rapidly. Each subtype of Batten Disease is caused by a mutation in one of several genes that are important for normal brain function. Common symptoms include vision loss, seizures, delay and eventual loss of skills previously acquired, dementia, and abnormal movements. Although the different forms of the disease may present at different ages, they are all fatal, usually by the teens or early twenties.\\nAt Circumvent, we are focused initially on CLN1 Batten Disease, which is one of the most common and most severe forms of Batten Disease. CLN1 Batten Disease is caused by a mutation in the CLN1 gene, which is responsible for removing a type of fatty acid called palmitate from proteins in the cell. When this gene is mutated, brain cells are unable to remove palmitate from proteins, which leads to rapid neurodegeneration early in childhood. Currently, there are no approved treatments for CLN1 Batten Disease.\\nCircumvent partners with Batten Disease patient organizations. These advocacy organizations support patients, families, and caregivers for these specific diseases and participate in research, advocacy, education and fundraising efforts.\\n![BDSRA+Logo+no+BG.png](https://static.wixstatic.com/media/8cf47c_81527f5567ed40469c4adf7c6bc16e2a~mv2.png/v1/fill/w_179,h_133,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/BDSRA%2BLogo%2Bno%2BBG.png)\\n![HH_new_logo.png](https://static.wixstatic.com/media/8cf47c_491f0c9c6e534293948b281d92b40fe3~mv2.png/v1/fill/w_52,h_32,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/HH_new_logo.png)\\n![welcome_logo_taylors-tale-logo-no-tag-4C](https://static.wixstatic.com/media/8cf47c_1aaa875c90db47de9558660497ccd16d~mv2.png/v1/crop/x_2,y_0,w_765,h_318/fill/w_55,h_23,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/welcome_logo_taylors-tale-logo-no-tag-4C.png)\\n![Zebra.png](https://static.wixstatic.com/media/8cf47c_3d6fc6bc17ae43b5835c9ee9cc1a2bb5~mv2.png/v1/fill/w_68,h_20,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/Zebra.png)\\nINVESTORS\\n## INVESTORS\\n![](https://static.wixstatic.com/media/8cf47c_0c639bac803b4a72bef96a0714d4a124~mv2.jpg/v1/crop/x_0,y_0,w_900,h_575/fill/w_144,h_92,al_c,q_80,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/8cf47c_0c639bac803b4a72bef96a0714d4a124~mv2.jpg)\\n![iUrYEOpJ.png](https://static.wixstatic.com/media/8cf47c_d521822d57734c9894cd338962ba4dd1~mv2.png/v1/fill/w_60,h_60,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/iUrYEOpJ.png)\\n![](https://static.wixstatic.com/media/8cf47c_8abc832652944a79afa624caaed8c3c7~mv2.jpeg/v1/fill/w_77,h_11,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/8cf47c_8abc832652944a79afa624caaed8c3c7~mv2.jpeg)\\n![](https://static.wixstatic.com/media/8cf47c_0ac27ae6b4c34997b1306cf4f2f21dd6~mv2.png/v1/crop/x_1,y_198,w_797,h_152/fill/w_70,h_13,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/8cf47c_0ac27ae6b4c34997b1306cf4f2f21dd6~mv2.png)\\n![getzgxj7jtwyv2bp83st.png](https://static.wixstatic.com/media/8cf47c_07340f75ad1a405db69c77e9cda81d4e~mv2.png/v1/fill/w_92,h_92,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/getzgxj7jtwyv2bp83st.png)\\nINVESTORS\\n## PARTNERS\\n![hms_logo_final_rgb_0.png](https://static.wixstatic.com/media/8cf47c_d527b752079c4e2e8db51b1c1ae2e551~mv2.png/v1/fill/w_68,h_22,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/hms_logo_final_rgb_0.png)\\n![AS_267465798422530_1440780223755_xl.png](https://static.wixstatic.com/media/8cf47c_5437cbd058114a07bfd219ded9296716~mv2.png/v1/fill/w_70,h_47,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/AS_267465798422530_1440780223755_xl.png)\\n![University-of-Michigan-Logo.png](https://static.wixstatic.com/media/8cf47c_25aea8309121467ea59370494063fdb0~mv2.png/v1/fill/w_54,h_30,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/University-of-Michigan-Logo.png)\\n![health_logo_2017.png](https://static.wixstatic.com/media/8cf47c_5cc3d695bf9745238141aa053ba9085b~mv2.png/v1/fill/w_116,h_77,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/health_logo_2017.png)\\n![STACKED_Gold&Black_Global_Logo.jpg](https://static.wixstatic.com/media/8cf47c_68d9c536d6614ef381baedea9b4b42a8~mv2.jpg/v1/fill/w_50,h_21,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/STACKED_Gold%26Black_Global_Logo.jpg)\\n![;w=600;h=315.jpeg](https://static.wixstatic.com/media/8cf47c_e736947710f3459ba38bb14176d3314e~mv2.jpeg/v1/crop/x_0,y_12,w_598,h_280/fill/w_55,h_26,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/%3Bw%3D600%3Bh%3D315.jpeg)\\n![UIC_Logo.png](https://static.wixstatic.com/media/8cf47c_e47d0f9e2e604b0ebf851ee42838606c~mv2.png/v1/fill/w_123,h_131,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/UIC_Logo.png)\\n![seattle-childrens-logo.png](https://static.wixstatic.com/media/8cf47c_6dc01d6646b4470582031b1a547f3a8a~mv2.png/v1/fill/w_60,h_31,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/seattle-childrens-logo.png)\\n![NIH-logo-1.jpg](https://static.wixstatic.com/media/8cf47c_f6d89e4c39984974b689cbd2f635141e~mv2.jpg/v1/fill/w_52,h_42,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/NIH-logo-1.jpg)\\n![waterloo.png](https://static.wixstatic.com/media/91fd6d_064831114c644ec2b337b98f190094a8~mv2.png/v1/fill/w_175,h_125,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/waterloo.png)\\n![uke_dachmarke_250x250px.png](https://static.wixstatic.com/media/8cf47c_8b2740f546364343be3dc1f278d26f7a~mv2.png/v1/fill/w_138,h_138,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/uke_dachmarke_250x250px.png)\\n![1024px-Duke_University_logo.svg.png](https://static.wixstatic.com/media/8cf47c_fe749e30028d4e0f9a4664000f4cb2f3~mv2.png/v1/fill/w_173,h_76,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/1024px-Duke_University_logo_svg.png)\\nPARTNERS\\nTEAM\\n![Office Desk](https://static.wixstatic.com/media/dc8702379d2144d6bd16b91480d1dbdc.jpg/v1/fill/w_176,h_117,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/dc8702379d2144d6bd16b91480d1dbdc.jpg)\\nAllen Yang\\nAndrew Lim\\nAnil Mukherjee\\nAnna Scott\\nAnne Danks\\nCarlos Pantoja\\nDaniel Chelsky\\nDevin Wiley\\nHarsh Jain\\n\\u200b\\nHarsukh Parmar\\nJohn Staropoli\\nLeah Appell\\nLen Post\\nLisa Hulle\\nMark Moore\\nMike Morgan\\nNader Al Nakouzi  Neal Anderson\\n\\u200b\\nPaul Rudnick\\nPaul Trippier\\nRachel M Johansson\\nRobert Steiner\\nRobert DeVita\\nSamy Hamdouche\\nSteven Duddy\\nStuart Lipton\\nTed Daley\\n\\u200b\\n## TEAM\\nTEAM\\nNeed more details? Contact us\\nWe are here to assist. Contact us by phone, email or via our social media channels.\\n[Contact Us](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com/contact>)\\nCONTACT\\nCircumvent FCOI Policy\\n[Download File](https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com/_files/ugd/91fd6d_8df4b5bc11a64596976c5b2851798fc5.pdf?index=true>)\\n© 2020 by Circumvent Pharmaceuticals, Inc.\\n  * [](https://www.circumventpharmaceuticals.com/<https:/www.linkedin.com/company/circumvent-pharmaceuticals>)\\n\\n\\nbottom of page\\n\" markdown_with_citations=\"top of page\\n![Circumvent_Logo-01.png⟨1⟩]\\n  * Home⟨2⟩\\n  * About⟨2⟩\\n  * Patients⟨2⟩\\n  * Investors⟨2⟩\\n  * Team⟨2⟩\\n  * More\\n\\n\\nUse tab to navigate through the menu items.\\n  * ABOUT⟨2⟩\\n  * APPROACH⟨2⟩\\n  * PATIENTS⟨2⟩\\n  * INVESTORS⟨2⟩\\n  * INVESTORS⟨2⟩\\n  * PARTNERS⟨2⟩\\n  * TEAM⟨2⟩\\n  * TEAM⟨2⟩\\n  * CONTACT⟨2⟩\\n\\n\\n![](https://static.wixstatic.com/media/8cf47c_5b88259224c94e6e8f86a331f645fc43f000.jpg/v1/fill/w_1080,h_600,al_c,q_85,usm_0.33_1.00_0.00,enc_avif,quality_auto/8cf47c_5b88259224c94e6e8f86a331f645fc43f000.jpg)\\nCIRCUMVENT\\n# Developing precision medicines for neurodegenerative disease\\n![Dial.png⟨3⟩]\\nABOUT\\n![shutterstock_726758389 \\\\[Converted\\\\]-01.jp](https://static.wixstatic.com/media/8cf47c_74e6e0d5e1aa4237afb64653322adc8b~mv2.jpg/v1/fill/w_1001,h_475,al_c,q_85,enc_avif,quality_auto/8cf47c_74e6e0d5e1aa4237afb64653322adc8b~mv2.jpg)\\n## ABOUT\\nIn the next 20 years, neurodegenerative disease is expected to overtake cancer as the second leading cause of death worldwide. At the same time, progress in developing disease-modifying treatments has been slowed by the lack of novel insights into driver mechanisms of disease. Circumvent was formed with the mission of developing precision medicines for neurodegenerative disease, starting with Batten Disease.\\nAPPROACH\\n## APPROACH\\nWe built an experienced team of scientists and clinicians to focus on diseases with high-fidelity, predictive animal models, a clear clinical development path, and the potential to reach the market quickly. Through our research and development of treatments for Batten Disease, we’ve uncovered new insights into brain-cell dysfunction that are common to numerous forms of neurological disease. We are now applying these insights across a variety of related diseases with diligence and precision.\\n![shutterstock_1197119914.jpg⟨4⟩]\\n## We've developed novel insights into:\\n![pasted image 0.png⟨5⟩]\\nSynaptic function Protein localization Lysosomal function Autophagy\\n![shutterstock_1197120001.jpg⟨6⟩]\\n![Embryonic Stem Cells⟨7⟩]\\n## The Palmitoylome\\nOur search for underlying biology has allowed us to characterize the palmitoylome with precision\\n\\u200b\\nWe are investigating several therapeutic strategies for modulating the palmitoylome\\n\\u200b\\nThis effort has broad potential to yield medicines for both rare and common forms of neurodegenerative disease\\n![Blood Test⟨8⟩]\\n## The Synaptome\\nOur investigation into the palmitoylome has given us unique insights into the architecture of the synaptome and its effect on synaptic function\\n\\u200b\\n>50% of palmitoylated proteins are synaptic proteins, and conversely, >40% of synaptic proteins are palmitoylated \\n\\u200b\\nModulating palmitoylation has effects on synaptic plasticity and neuronal differentiation, with broad therapeutics potential\\n## PATIENTS\\nOur priority is to meet the needs of patients through the development of precision medicines for rare neurological diseases. We listen to patients and caregivers and solicit advice to better understand expectations for therapies and guide our research and development efforts. Circumvent’s current drug programs are being developed for Batten Disease and other rare neurological disorders.\\n![shutterstock_386773696.jpg⟨9⟩]\\nPATIENTS\\n## What is Batten Disease?\\nBatten disease is a group of rare neurodegenerative diseases that typically present during childhood and progress rapidly. Each subtype of Batten Disease is caused by a mutation in one of several genes that are important for normal brain function. Common symptoms include vision loss, seizures, delay and eventual loss of skills previously acquired, dementia, and abnormal movements. Although the different forms of the disease may present at different ages, they are all fatal, usually by the teens or early twenties.\\nAt Circumvent, we are focused initially on CLN1 Batten Disease, which is one of the most common and most severe forms of Batten Disease. CLN1 Batten Disease is caused by a mutation in the CLN1 gene, which is responsible for removing a type of fatty acid called palmitate from proteins in the cell. When this gene is mutated, brain cells are unable to remove palmitate from proteins, which leads to rapid neurodegeneration early in childhood. Currently, there are no approved treatments for CLN1 Batten Disease.\\nCircumvent partners with Batten Disease patient organizations. These advocacy organizations support patients, families, and caregivers for these specific diseases and participate in research, advocacy, education and fundraising efforts.\\n![BDSRA+Logo+no+BG.png⟨10⟩]\\n![HH_new_logo.png⟨11⟩]\\n![welcome_logo_taylors-tale-logo-no-tag-4C⟨12⟩]\\n![Zebra.png⟨13⟩]\\nINVESTORS\\n## INVESTORS\\n![](https://static.wixstatic.com/media/8cf47c_0c639bac803b4a72bef96a0714d4a124~mv2.jpg/v1/crop/x_0,y_0,w_900,h_575/fill/w_144,h_92,al_c,q_80,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/8cf47c_0c639bac803b4a72bef96a0714d4a124~mv2.jpg)\\n![iUrYEOpJ.png⟨14⟩]\\n![](https://static.wixstatic.com/media/8cf47c_8abc832652944a79afa624caaed8c3c7~mv2.jpeg/v1/fill/w_77,h_11,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/8cf47c_8abc832652944a79afa624caaed8c3c7~mv2.jpeg)\\n![](https://static.wixstatic.com/media/8cf47c_0ac27ae6b4c34997b1306cf4f2f21dd6~mv2.png/v1/crop/x_1,y_198,w_797,h_152/fill/w_70,h_13,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/8cf47c_0ac27ae6b4c34997b1306cf4f2f21dd6~mv2.png)\\n![getzgxj7jtwyv2bp83st.png⟨15⟩]\\nINVESTORS\\n## PARTNERS\\n![hms_logo_final_rgb_0.png⟨16⟩]\\n![AS_267465798422530_1440780223755_xl.png⟨17⟩]\\n![University-of-Michigan-Logo.png⟨18⟩]\\n![health_logo_2017.png⟨19⟩]\\n![STACKED_Gold&Black_Global_Logo.jpg⟨20⟩]\\n![;w=600;h=315.jpeg⟨21⟩]\\n![UIC_Logo.png⟨22⟩]\\n![seattle-childrens-logo.png⟨23⟩]\\n![NIH-logo-1.jpg⟨24⟩]\\n![waterloo.png⟨25⟩]\\n![uke_dachmarke_250x250px.png⟨26⟩]\\n![1024px-Duke_University_logo.svg.png⟨27⟩]\\nPARTNERS\\nTEAM\\n![Office Desk⟨28⟩]\\nAllen Yang\\nAndrew Lim\\nAnil Mukherjee\\nAnna Scott\\nAnne Danks\\nCarlos Pantoja\\nDaniel Chelsky\\nDevin Wiley\\nHarsh Jain\\n\\u200b\\nHarsukh Parmar\\nJohn Staropoli\\nLeah Appell\\nLen Post\\nLisa Hulle\\nMark Moore\\nMike Morgan\\nNader Al Nakouzi  Neal Anderson\\n\\u200b\\nPaul Rudnick\\nPaul Trippier\\nRachel M Johansson\\nRobert Steiner\\nRobert DeVita\\nSamy Hamdouche\\nSteven Duddy\\nStuart Lipton\\nTed Daley\\n\\u200b\\n## TEAM\\nTEAM\\nNeed more details? Contact us\\nWe are here to assist. Contact us by phone, email or via our social media channels.\\nContact Us⟨29⟩\\nCONTACT\\nCircumvent FCOI Policy\\nDownload File⟨30⟩\\n© 2020 by Circumvent Pharmaceuticals, Inc.\\n  * [](https://www.circumventpharmaceuticals.com/<https:/www.linkedin.com/company/circumvent-pharmaceuticals>)\\n\\n\\nbottom of page\\n\" references_markdown='\\n\\n## References\\n\\n⟨1⟩ https://static.wixstatic.com/media/8cf47c_e286387e91c748aab201e7933ddc0caf~mv2.png/v1/fill/w_200,h_52,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Circumvent_Logo-01.png: Circumvent_Logo-01.png\\n⟨2⟩ https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com>: Home\\n⟨3⟩ https://static.wixstatic.com/media/8cf47c_268dcd55d6ba41779fe5a776056582da~mv2.png/v1/fill/w_132,h_135,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Dial.png: Dial.png\\n⟨4⟩ https://static.wixstatic.com/media/8cf47c_8482c4e53b0a4b3594e5d0107d522ec4~mv2.jpg/v1/crop/x_60,y_56,w_5000,h_2769/fill/w_1000,h_556,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_1197119914.jpg: shutterstock_1197119914.jpg\\n⟨5⟩ https://static.wixstatic.com/media/8cf47c_c01544d4f1de4a1eb8e3caa8932f4d3d~mv2.png/v1/fill/w_105,h_79,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/pasted%20image%200.png: pasted image 0.png\\n⟨6⟩ https://static.wixstatic.com/media/8cf47c_f726d65afb7848109b0b23f0c803e764~mv2.jpg/v1/fill/w_132,h_74,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/8cf47c_f726d65afb7848109b0b23f0c803e764~mv2.jpg: shutterstock_1197120001.jpg\\n⟨7⟩ https://static.wixstatic.com/media/5c3f1e5a1ebf435bbc152173d50d7ea9.jpg/v1/fill/w_94,h_75,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/5c3f1e5a1ebf435bbc152173d50d7ea9.jpg: Embryonic Stem Cells\\n⟨8⟩ https://static.wixstatic.com/media/a5b6e8edfb63432792f48f95895df268.jpg/v1/fill/w_112,h_75,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/a5b6e8edfb63432792f48f95895df268.jpg: Blood Test\\n⟨9⟩ https://static.wixstatic.com/media/8cf47c_e107cebcb2bb4375a728edf7387082e5~mv2.jpg/v1/crop/x_251,y_430,w_4679,h_2596/fill/w_150,h_83,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/shutterstock_386773696.jpg: shutterstock_386773696.jpg\\n⟨10⟩ https://static.wixstatic.com/media/8cf47c_81527f5567ed40469c4adf7c6bc16e2a~mv2.png/v1/fill/w_179,h_133,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/BDSRA%2BLogo%2Bno%2BBG.png: BDSRA+Logo+no+BG.png\\n⟨11⟩ https://static.wixstatic.com/media/8cf47c_491f0c9c6e534293948b281d92b40fe3~mv2.png/v1/fill/w_52,h_32,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/HH_new_logo.png: HH_new_logo.png\\n⟨12⟩ https://static.wixstatic.com/media/8cf47c_1aaa875c90db47de9558660497ccd16d~mv2.png/v1/crop/x_2,y_0,w_765,h_318/fill/w_55,h_23,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/welcome_logo_taylors-tale-logo-no-tag-4C.png: welcome_logo_taylors-tale-logo-no-tag-4C\\n⟨13⟩ https://static.wixstatic.com/media/8cf47c_3d6fc6bc17ae43b5835c9ee9cc1a2bb5~mv2.png/v1/fill/w_68,h_20,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/Zebra.png: Zebra.png\\n⟨14⟩ https://static.wixstatic.com/media/8cf47c_d521822d57734c9894cd338962ba4dd1~mv2.png/v1/fill/w_60,h_60,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/iUrYEOpJ.png: iUrYEOpJ.png\\n⟨15⟩ https://static.wixstatic.com/media/8cf47c_07340f75ad1a405db69c77e9cda81d4e~mv2.png/v1/fill/w_92,h_92,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/getzgxj7jtwyv2bp83st.png: getzgxj7jtwyv2bp83st.png\\n⟨16⟩ https://static.wixstatic.com/media/8cf47c_d527b752079c4e2e8db51b1c1ae2e551~mv2.png/v1/fill/w_68,h_22,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/hms_logo_final_rgb_0.png: hms_logo_final_rgb_0.png\\n⟨17⟩ https://static.wixstatic.com/media/8cf47c_5437cbd058114a07bfd219ded9296716~mv2.png/v1/fill/w_70,h_47,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/AS_267465798422530_1440780223755_xl.png: AS_267465798422530_1440780223755_xl.png\\n⟨18⟩ https://static.wixstatic.com/media/8cf47c_25aea8309121467ea59370494063fdb0~mv2.png/v1/fill/w_54,h_30,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/University-of-Michigan-Logo.png: University-of-Michigan-Logo.png\\n⟨19⟩ https://static.wixstatic.com/media/8cf47c_5cc3d695bf9745238141aa053ba9085b~mv2.png/v1/fill/w_116,h_77,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/health_logo_2017.png: health_logo_2017.png\\n⟨20⟩ https://static.wixstatic.com/media/8cf47c_68d9c536d6614ef381baedea9b4b42a8~mv2.jpg/v1/fill/w_50,h_21,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/STACKED_Gold%26Black_Global_Logo.jpg: STACKED_Gold&Black_Global_Logo.jpg\\n⟨21⟩ https://static.wixstatic.com/media/8cf47c_e736947710f3459ba38bb14176d3314e~mv2.jpeg/v1/crop/x_0,y_12,w_598,h_280/fill/w_55,h_26,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/%3Bw%3D600%3Bh%3D315.jpeg: ;w=600;h=315.jpeg\\n⟨22⟩ https://static.wixstatic.com/media/8cf47c_e47d0f9e2e604b0ebf851ee42838606c~mv2.png/v1/fill/w_123,h_131,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/UIC_Logo.png: UIC_Logo.png\\n⟨23⟩ https://static.wixstatic.com/media/8cf47c_6dc01d6646b4470582031b1a547f3a8a~mv2.png/v1/fill/w_60,h_31,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/seattle-childrens-logo.png: seattle-childrens-logo.png\\n⟨24⟩ https://static.wixstatic.com/media/8cf47c_f6d89e4c39984974b689cbd2f635141e~mv2.jpg/v1/fill/w_52,h_42,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/NIH-logo-1.jpg: NIH-logo-1.jpg\\n⟨25⟩ https://static.wixstatic.com/media/91fd6d_064831114c644ec2b337b98f190094a8~mv2.png/v1/fill/w_175,h_125,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/waterloo.png: waterloo.png\\n⟨26⟩ https://static.wixstatic.com/media/8cf47c_8b2740f546364343be3dc1f278d26f7a~mv2.png/v1/fill/w_138,h_138,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/uke_dachmarke_250x250px.png: uke_dachmarke_250x250px.png\\n⟨27⟩ https://static.wixstatic.com/media/8cf47c_fe749e30028d4e0f9a4664000f4cb2f3~mv2.png/v1/fill/w_173,h_76,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_avif,quality_auto/1024px-Duke_University_logo_svg.png: 1024px-Duke_University_logo.svg.png\\n⟨28⟩ https://static.wixstatic.com/media/dc8702379d2144d6bd16b91480d1dbdc.jpg/v1/fill/w_176,h_117,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/dc8702379d2144d6bd16b91480d1dbdc.jpg: Office Desk\\n⟨29⟩ https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com/contact>: Contact Us\\n⟨30⟩ https://www.circumventpharmaceuticals.com/<https:/www.circumventpharmaceuticals.com/_files/ugd/91fd6d_8df4b5bc11a64596976c5b2851798fc5.pdf?index=true>: Download File\\n' fit_markdown='' fit_html=''",
  "generated_description": "**Company Overview: Circumvent Pharmaceuticals**\n\n**Mission:** Circumvent Pharmaceuticals is on a critical mission to leverage monogenic disorders as a lens to inform and address complex issues in neurodegenerative diseases. Essentially, they're looking to harness insights from rare diseases to develop targeted therapies that could change the game in treating common neurological conditions.\n\n**Background:** Founded as part of Y Combinator Batch S18, Circumvent focuses specifically on creating precision medicines for neurodegenerative diseases like Batten Disease—an area often neglected in mainstream medicine. Their approach is rooted in understanding the intricate biological processes underlying these disorders, thus paving the way for innovative treatments.\n\n**Location and Team:** Although specific location details weren't provided, Circumvent operates with a dedicated team of six professionals who are committed to advancing research and treatment options in the biotech space.\n\n**Core Focus Areas:** Tagged as a startup working in the realms of neurotechnology, biotech, and genomics, Circumvent aims to unravel the complexities of neurological disorders through research, particularly with high-fidelity animal models that provide predictive insights into clinical outcomes.\n\n**Strategic Approach:**\n- **Precision Medicine:** Circumvent tackles diseases like Batten Disease, a rapidly progressing neurological disorder that currently has no approved treatments, with an understanding gained through genetics and disease mechanisms.\n- **Innovation in Drug Development:** By studying the palmitoylome (which involves fatty acids’ role in brain function) and synaptic architecture, Circumvent is uncovering new strategies that could lead to effective therapies not only for rare diseases like CLN1 Batten Disease but potentially for a range of common neurodegenerative disorders.\n\n**Patient-Centric Development:** Circumvent is deeply entrenched in listening to patients and caregivers, aiming to align their research with the real needs and expectations of those affected by these challenging conditions. This engagement helps guide their R&D efforts and ensures a focus on impactful results.\n\n**Collaborations and Advocacy:** They partner with advocacy organizations for Batten Disease to foster support and research efforts, recognizing the importance of community and shared knowledge in advancing drug development.\n\n**Get Involved:** If you’re a stakeholder in the realm of rare genetic disorders, Circumvent is open to dialogue. Their website offers more avenues to connect, either for patients, caregivers, or potential partners.\n\n**Conclusion:** Circumvent Pharmaceuticals stands at the intersection of innovation and necessity, taking a focused approach to develop treatments for debilitating neurodegenerative diseases while rooted in a patient-first methodology. Their work could be crucial in changing the way we approach therapies for some of the most challenging health issues of our time. For more information, check out their website [here](https://www.circumventpharmaceuticals.com/)."
}